https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29666 10 mg/L, or who were taking anti-inflammatory medications or n-3PUFA supplements, 126 participants (age 77.6 ± 7.3 years; females, 46%) were included in the analysis. After multivariate adjustments, O3I was inversely associated with CRP (β = −0.209, p < 0.05) and monocyte cell counts (β = −0.205, p < 0.05), and total n-3PUFA was inversely related to WBC (β = −0.238, p < 0.05), neutrophils (β = −0.212, p < 0.05) and monocytes (β = −0.246, p < 0.05). However no association between fibrinogen and O3I or total n-3PUFA was detected. Conclusions: This study demonstrated a negative association between O3I and biomarkers of inflammation in an older population. The findings support a potential role for n-3PUFA supplementation in the management of inflammatory diseases.]]> Wed 11 Apr 2018 16:52:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30590 Wed 11 Apr 2018 10:46:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20803 Sat 24 Mar 2018 08:05:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4972 Sat 24 Mar 2018 07:46:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28945 Sat 24 Mar 2018 07:31:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50970 Mon 14 Aug 2023 15:19:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37289 n = 99-218, depending on case definition) collected prospectively in population-based studies conducted in Australia, France, the Netherlands, Slovakia, and the UK were pooled along with secondary data on a sample of control women (n = 4,938) collected in Australia and the UK. Risk factors for AFE were investigated by comparing the women with AFE in Australia and the UK with the control women identified in these countries using logistic regression. Factors associated with poor maternal outcomes (fatality and composite of fatality or permanent neurological injury) amongst women with AFE from each of the countries were investigated using logistic regression or Wilcoxon rank-sum test. The estimated incidence of AFE ranged from 0.8-1.8 per 100,000 maternities, and the proportion of women with AFE who died or had permanent neurological injury ranged from 30%-41%, depending on the case definition. However, applying different case definitions did not materially alter findings regarding risk factors for AFE and factors associated with poor maternal outcomes amongst women with AFE. Using the most liberal case definition (UK) and adjusting for the severity of presentation when appropriate, women who died were more likely than those who survived to present with cardiac arrest (89% versus 40%, adjusted odds ratio [aOR] 10.58, 95% confidence interval [CI] 3.93-28.48, p < 0.001) and less likely to have a source of concentrated fibrinogen (40% versus 56%, aOR 0.44, 95% CI 0.21-0.92, p = 0.029) or platelets given (24% versus 49%, aOR 0.23, 95% CI 0.10-0.52, p < 0.001). They also had a lower dose of tranexamic acid (median dose 0.7 g versus 2 g, p = 0.035) and were less likely to have had an obstetrician and/or anaesthetist present at the time of the AFE (61% versus 75%, aOR 0.38, 95% CI 0.16-0.90, p = 0.027). Limitations of the study include limited statistical power to examine factors associated with poor maternal outcome and the potential for residual confounding or confounding by indication. Conclusions: The findings of our study suggest that when an AFE is suspected, initial supportive obstetric care is important, but having an obstetrician and/or anaesthetist present at the time of the AFE event and use of interventions to correct coagulopathy, including the administration of an adequate dose of tranexamic acid, may be important to improve maternal outcome. Future research should focus on early detection of the coagulation deficiencies seen in AFE alongside the role of tranexamic acid and other coagulopathy management strategies.]]> Fri 18 Sep 2020 11:47:19 AEST ]]>